Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 165, Issue 5, Pages 640-648Publisher
WILEY-BLACKWELL
DOI: 10.1111/bjh.12801
Keywords
PCNSL; HGAL; BCL6; LMO2; prognosis
Categories
Funding
- National Institutes of Health (NIH) [NIH CA109335]
- Lymphoma Research Foundation
- Dwoskin Family Foundation
- Recio Family Foundation
- Anthony Rizzo Family Foundation
Ask authors/readers for more resources
Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX-based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52%, 65% and 56% of tumours, respectively. BCL6 protein expression was associated with longer progression-free survival (P=0006) and overall survival (OS, P=005), while expression of LMO2 protein was associated with longer OS (P=0027). Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available